MoonLake Immunotherapeutics
MLTX$1.14B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaZUG100 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
4
Next Catalyst
Mar 27, 2026
13dMarket Overview
Stock performance and key metrics
MLTX News
Catalyst Timeline
4 upcoming, 1 past
Phase 3Next
Sonelokimab Phase 3 Results Expected
Mar 27, 2026EstimatedSonelokimab35
Primary completion for Sonelokimab trial (NCT06768671) in Hidradenitis Suppurativa
Source3 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Drug Pipeline
Sonelokimab
Hidradenitis Suppurativa
Risankizumab
Arthritis, Psoriatic
Adalimumab
Arthritis, Psoriatic
Sonelokimab (M1095)
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sonelokimab | Phase 3 | Hidradenitis Suppurativa | - | - |
Risankizumab | Phase 3 | Arthritis, Psoriatic | - | - |
Adalimumab | Phase 2 | Arthritis, Psoriatic | - | - |
Sonelokimab (M1095) | Phase 2 | Hidradenitis Suppurativa | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply